Semanteon Capital Management LP Invests $1.13 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Semanteon Capital Management LP acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 105,868 shares of the biopharmaceutical company's stock, valued at approximately $1,131,000.

A number of other hedge funds have also recently bought and sold shares of FOLD. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 1,884 shares during the last quarter. Legacy Capital Group California Inc. purchased a new position in Amicus Therapeutics in the third quarter worth $206,000. Assenagon Asset Management S.A. grew its stake in Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock valued at $21,765,000 after purchasing an additional 1,192,489 shares during the period. Blue Trust Inc. grew its stake in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,831 shares during the period. Finally, nVerses Capital LLC purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at $187,000.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $10,382,718.34. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 22,500 shares of company stock valued at $244,875 over the last ninety days. Corporate insiders own 2.20% of the company's stock.

Amicus Therapeutics Price Performance

NASDAQ FOLD traded down $0.17 during trading hours on Monday, reaching $11.52. The company's stock had a trading volume of 2,095,273 shares, compared to its average volume of 2,731,345. The firm's 50-day moving average price is $11.18 and its 200-day moving average price is $10.56. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. The company has a market capitalization of $3.41 billion, a price-to-earnings ratio of -23.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts' consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The business had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. During the same quarter last year, the firm posted ($0.15) EPS. The company's revenue for the quarter was up 34.0% on a year-over-year basis. On average, equities research analysts predict that Amicus Therapeutics, Inc. will post -0.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

FOLD has been the topic of a number of research analyst reports. Bank of America boosted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, October 17th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a "buy" rating and a $18.00 target price for the company. Morgan Stanley lowered their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. decreased their target price on Amicus Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a research report on Friday, August 16th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Amicus Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $17.13.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.